Mesa Laboratories (NASDAQ:MLAB) Stock Price Passes Above 200-Day Moving Average – Here’s What Happened

Mesa Laboratories, Inc. (NASDAQ:MLAB)’s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $79.16 and traded as high as $82.50. Mesa Laboratories shares last traded at $81.13, with a volume of 99,075 shares traded.

Analyst Ratings Changes

Several brokerages have issued reports on MLAB. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Mesa Laboratories in a research note on Thursday, January 22nd. Wall Street Zen raised Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 7th. Wells Fargo & Company raised their price objective on shares of Mesa Laboratories from $83.00 to $94.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 4th. Finally, Zacks Research upgraded shares of Mesa Laboratories from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus target price of $94.00.

Mesa Laboratories Trading Down 1.5%

The business’s 50-day simple moving average is $86.77 and its two-hundred day simple moving average is $79.16. The firm has a market capitalization of $447.84 million, a price-to-earnings ratio of 126.77 and a beta of 0.85. The company has a quick ratio of 1.45, a current ratio of 1.94 and a debt-to-equity ratio of 0.86.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings data on Tuesday, February 3rd. The medical instruments supplier reported $3.07 EPS for the quarter, topping the consensus estimate of $2.41 by $0.66. The firm had revenue of $65.13 million for the quarter, compared to analyst estimates of $63.23 million. Mesa Laboratories had a net margin of 1.51% and a return on equity of 22.02%. Equities analysts forecast that Mesa Laboratories, Inc. will post 8 earnings per share for the current year.

Mesa Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 16th. Shareholders of record on Saturday, February 28th were paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Friday, February 27th. Mesa Laboratories’s dividend payout ratio is 100.00%.

Insider Activity

In other news, Director Shiraz Shabanali Ladiwala bought 3,500 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was bought at an average cost of $72.23 per share, for a total transaction of $252,805.00. Following the acquisition, the director directly owned 8,523 shares of the company’s stock, valued at $615,616.29. The trade was a 69.68% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director R Tony Tripeny purchased 1,315 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were acquired at an average price of $76.00 per share, for a total transaction of $99,940.00. Following the completion of the purchase, the director directly owned 5,398 shares of the company’s stock, valued at approximately $410,248. This trade represents a 32.21% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 6,116 shares of company stock valued at $452,076. 4.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Mesa Laboratories

A number of large investors have recently modified their holdings of MLAB. Mason Capital Management LLC purchased a new position in Mesa Laboratories in the third quarter valued at $4,711,000. Herald Investment Management Ltd increased its holdings in Mesa Laboratories by 300.0% during the 3rd quarter. Herald Investment Management Ltd now owns 50,000 shares of the medical instruments supplier’s stock worth $3,340,000 after purchasing an additional 37,500 shares during the period. Crawford Investment Counsel Inc. increased its holdings in Mesa Laboratories by 59.4% during the 3rd quarter. Crawford Investment Counsel Inc. now owns 82,467 shares of the medical instruments supplier’s stock worth $5,526,000 after purchasing an additional 30,723 shares during the period. Diamond Hill Capital Management Inc. raised its position in Mesa Laboratories by 218.0% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 123,381 shares of the medical instruments supplier’s stock valued at $8,268,000 after purchasing an additional 84,582 shares in the last quarter. Finally, Roubaix Capital LLC acquired a new stake in Mesa Laboratories in the 3rd quarter valued at about $5,137,000. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.